Feedback plc

Feedback plc is a medical technology company, headquartered in London, UK, and established in 1958, that supplies specialized software and systems to individuals and organizations working within the medical imaging sector. Their product portfolio includes TexRAD, a patented software tool designed to extract and quantify textural features within radiological images. This assists research into all types of tumors and helps uncover biomarkers in medical imagery. They also offer TexRAD Lung, a specific software tool used for the clinical analysis of lung cancer within the European Union. Additionally, the company provides the Cadran image platform, a robust picture archiving and communication system (PACS) for hospitals and research institutes, capable of handling images from various imaging modalities like CT and PET scanners. Another key offering is Bleepa, a secure platform for clinical communications that facilitates the safe sharing of high-quality medical images.

Feedback plc trades as FDBK.L on LSE. The company is classified in Healthcare / Medical - Healthcare Information Services and reports in GBP.

The current profile places the business in Medical - Healthcare Information Services. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows £885,623 of revenue and -£7.32M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Feedback plc can be compared against peers such as Chill Brands Group PLC, CRISM Therapeutics Corporation, Genedrive Plc, MyHealthChecked PLC, N4 Pharma Plc, Polarean Imaging plc.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of £3.35M, beta of -0.09, and return on equity of N/A.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

FDBK.L currently shows total debt of £0 and beta of -0.09. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://fbkmed.com/feedback-plc

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.